Anti-aging peptides in Panama: 19-trial meta-analysis and the law

In Panama, the anti-aging peptide is sold in three formats that the literature and the law treat differently: the cream or serum, the oral collagen supplement and the injectable vial. A meta-analysis published in March 2026 finally allows a look at the pooled evidence for the first two. This article summarizes it using the exact figures in the published abstract and sets it against what the National Directorate of Pharmacy and Drugs (DNFD) of the Ministry of Health (Minsa) has put in writing about what a cosmetic can be. It is evidence and regulatory analysis, not a usage recommendation.

What the 19-trial meta-analysis found

The work by Nukaly and colleagues, published in Frontiers in Medicine on March 17, 2026, is a systematic review and meta-analysis of randomized trials of oral and topical peptides for skin aging. It searched MEDLINE, CENTRAL and Web of Science following PRISMA guidelines, assessed risk of bias with the RoB 2 tool and pooled the data with a random-effects model¹.

It analyzed 19 trials with 1,341 participants. Peptides, particularly oral formulations, significantly improved hydration and brightness, with a modest pooled effect on wrinkle reduction (MD = 0.27; p = 0.04). Subgroup analysis indicated that this benefit was largely driven by oral polypeptides (MD = 1.5; p = 0.01). Effects on elasticity and density were inconsistent, and adverse events were minimal¹. The abstract does not state the units of the mean difference or give a separate figure for topical peptides, so it should not be extrapolated to a specific cream.

The authors conclude that peptides appear safe but call for larger trials with standardized outcomes and histopathologic assessment¹. They declare no commercial or financial relationships that could be construed as a conflict of interest¹.

Oral versus topical: why the difference matters

That the wrinkle effect depends on oral products is the least comfortable finding for cream marketing. An earlier meta-analysis of 26 trials with 1,721 patients on oral hydrolyzed collagen found significant improvements in hydration (Z = 4.94; p < 0.00001) and elasticity (Z = 4.49; p < 0.00001) versus placebo, although it identified several biases in the included studies⁶. That body of evidence concerns ingested supplements, not cosmetics.

For peptides applied to the skin, the barrier is different. The so-called 500 dalton rule holds that molecules above that size hardly cross the stratum corneum¹². In hairless mouse skin, the pentapeptide KTTKS and its palmitoylated derivative degraded rapidly in skin extracts; neither reached the receptor fluid, and only the palmitoylated derivative was detected in every layer, at 0.3 μg/cm² in the dermis¹¹. For the copper complex GHK-Cu, an in vitro study measured copper and found it crossed dissected human skin in potentially therapeutic amounts¹³, while a 2025 review notes that published information on its permeability and efficacy is insufficient and that clinical studies are lacking⁸.

What creams do have: small, heterogeneous trials

Favorable topical trials exist. One double-blind, placebo-controlled, split-face trial in 93 women aged 35 to 55 showed, at 12 weeks, improved fine lines and wrinkles with 3 ppm palmitoyl-KTTKS versus the base cream, with good tolerance¹⁰. But the overall picture is different: a systematic review found 15 studies of extracellular-matrix-stimulating peptides in cosmetics, only 6 of which used a placebo control and 5 double blinding; the literature, its authors say, is sparse with many methodological limitations⁷. A classic review sorted topical peptides into signal, enzyme-inhibitor, neurotransmitter-inhibitor and carrier groups and included only controlled studies¹⁴.

GHK-Cu illustrates the problem: in a randomized trial of 13 patients after CO2 laser resurfacing, objective assessment showed no wrinkle improvement attributable to the peptide and only subjective satisfaction was higher (P = 0.04)⁹. We covered it in GHK-Cu creams in Panama, and in Botox in a cream and argireline we saw the same pattern of promise versus evidence. On signal peptides such as palmitoyl pentapeptide, see Matrixyl and signal peptides.

Where Panama draws the line: Note 010/2024 and article 208

On October 14, 2024, the DNFD issued Note 010/SCV/DFV/DNFD-2024, a cosmetic product safety note signed by its national director, Uriel B. Pérez M. Although it deals with fragrances, its "Situation in Panama" section sets the criteria separating a cosmetic from a medicine²:

• The Central American Technical Regulation RTCA 71.03.35:21 states that a cosmetic product to which therapeutic properties are attributed because of its composition must be registered as a medicine².
• RTCA 71.03.36:21, on labeling, prohibits misleading claims and claims of therapeutic properties for any condition or products specific to the treatment of skin and appendage dysfunctions².
• Article 208 of Executive Decree 27 of May 10, 2024, which regulates Law 419 of 2024, states: "All products that indicate the cure of a disease, or any product that can be ingested, inhaled or injected into the human body, are not considered cosmetic products, since these must only be applied topically"²³.

Article 207 of the same decree adds that additional label information must conform to the properties derived from the formula and that "the declaration of properties that cannot be verified is prohibited"³. In practice: a cream may claim hydration; promising to "treat" acne, sagging as a disease or hair loss pushes it toward medicine. And an oral collagen, however many trials it has, cannot be registered as a cosmetic in Panama under article 208. The cited texts do not say which other health category it fits; that depends on other rules this article does not analyze²³.

The DNFD does cancel cosmetic registrations

This is not a dormant rule. DNFD Resolution No. 100 of July 7, 2026 canceled health registrations 106521 and 106527 for two sunscreens after a European Commission alert for lilial (BMHCA), and Minsa asked the public to "buy cosmetics with a valid health registration"⁴; the full case is in our BMHCA analysis. On September 1, 2026, Minsa launched a national campaign against counterfeit medicines with the National Customs Authority, the Public Ministry, the Ministry of Public Security and the University of Panama, and referred to multiple cancellations of registrations for medicines and cosmetics circulating without authorization⁵. The 2024 note also lets users report adverse effects of cosmetics to the Cosmetovigilance Section using a Minsa form².

How to read a peptide cosmetic

• Check the cosmetic health registration number before anything else²⁴.
• Compare the promise with what the evidence supports: hydration and brightness have pooled backing; elasticity and density do not, consistently¹.
• Ask whether there is a placebo-controlled trial of the product itself or only studies of the ingredient⁷.
• Be wary of any ingestible or injectable presentation advertised as cosmetic: under article 208, it is not³.
• If there is a reaction, report it to the Cosmetovigilance Section².